<DOC>
	<DOCNO>NCT02931513</DOCNO>
	<brief_summary>Primary biliary cholangitis ( PBC ) autoimmune chronic liver disease , characterise destruction small intrahepatic bile duct . Ursodeoxycholic acid ( UDCA ) first line treatment patient PBC . However , 40 % patient respond inadequate treatment . sCD163 macrophage activation marker shedded plasma macrophage liver . sMR soluble mannose receptor . The investigator want investigate whether sCD163 sMR predict response treatment UDCA newly diagnose patient PBC .</brief_summary>
	<brief_title>sCD163 PBC Patients - Assessment Treatment Response</brief_title>
	<detailed_description>Primary biliary cholangitis ( PBC , previously call 'primary biliary cirrhosis ' ) autoimmune cholestatic liver disease characterize destruction intrahepatic bile duct progression liver fibrosis cirrhosis . In pre-cirrhotic phase , fatigue pruritus dominant symptom . These symptom reduce PBC patient ' quality life , extent cause patient leave work force seek disability pension unknown . The diagnosis PBC base presence two three major criterion ; unexplained serum alkaline phosphatase ( ALP ) &gt; 1.5 time upper normal limit 24 week , presence anti-mitochondrial antibody ( AMA ) , compatible liver histology . Multiple model conduct predict prognosis patient PBC . The Mayo risk score best validate include information age , bilirubin , albumin , prothrombin time peripheral oedema . Other prognostic factor pruritus fatigue diagnosis predict time develop cirrhosis complication . Ursodeoxycholic acid first line treatment patient PBC . Response treatment assess 12 month treatment use e.g . Paris 1 criterion ( ALP &lt; 3 time upper normal limit , AST &lt; 2 time upper normal limit , bilirubin â‰¤1 mg/dL one year treatment ) . Up 40 % patient respond inadequately UDCA need add-on therapy . ( e.g . fibrates , budenosid obeticholic acid ) . In PBC , inflammation attribute immune response mitochondrial autoantigens follow serologic response anti-mitochondrial antibody ( AMAs ) ; accompany inflammation small bile duct . The pathogenesis include CD4 CD8 cell , presence biliary cell express 2-oxo-dehydrogenase pathway ( PDC-E2 ) activate macrophage via granulocyte macrophage colony-stimulating factor . The activated macrophage , together AMAs , produce proinflammatory response subsequent liver inflammation fibrosis . Thus , macrophage seem involve PBC disease severity progression . However , macrophage activation marker previously investigate PBC patient . The investigator research group last year investigate macrophage activation marker sCD163 . The group show increased level relation liver fibrosis/cirrhosis patient chronic viral hepatitis ( HBV HCV ) , non-alcoholic fatty liver disease ( NAFLD/NASH ) alcoholic liver disease ( alcoholic hepatitis cirrhosis ) liver disease severity include risk portal hypertension development complication mortality . Just recently investigator ' group also demonstrate soluble mannose receptor ( sMR ) sCD163 associate early long-term prognosis patient cirrhosis acute-on-chronic liver failure . Aims : To investigate sCD163 sMR diagnosis , treatment UDCA , possible predictor non-response UDCA treatment thus predictor patient need add-on therapy .</detailed_description>
	<mesh_term>Inflammation</mesh_term>
	<mesh_term>Liver Cirrhosis , Biliary</mesh_term>
	<mesh_term>Hepatitis</mesh_term>
	<criteria>Newly diagnose Primary biliary cholangitis No treatment UDCA Patient 18 year Expected lifetime 6 month Expected liver transplantation within 6 month Liver cancer Cirrhosis cause</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2016</verification_date>
</DOC>